专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明授权

US5100702A Thin platinum film-forming composition 失效
标题翻译：薄铂成膜组合物
公开(公告)号：US5100702A
公开(公告)日：1992-03-31
申请号：US656880
申请日：1991-02-19
申请人： Koichi Maeda , Ryozo Sakoda , Hideki Takamatsu
发明人： Koichi Maeda , Ryozo Sakoda , Hideki Takamatsu
IPC分类号： C07F15/00 , C23C18/08 , H05K3/10
CPC分类号： C23C18/08 , C07F15/0086 , H05K3/105
摘要： A thin platinum film is formed on a substrate of glass, alumina or pottery by applying on the surface of the substrate a solution containing one part by weight of an organic platinum complex represented by formula (I):PT (R.sup.1 --C.tbd.C--R.sup.2).sub.2 (I)wherein R.sup.1 and R.sup.2 each represents a group of phenyl, 4-methylphenyl or 4-methoxyphenyl and 0.1 to 100 parts by weight of an organic solvent dissolving the complex, then heating the coated film at the decomposition temperature of the complex and thereafter firing the film and 400.degree. to 900.degree. C.
摘要翻译：在玻璃，氧化铝或陶器的基材上形成薄的铂膜，在基材的表面上涂布含有1重量份式（I）表示的有机铂络合物的溶液：PT（R1-C 3BOND C- R2）2（I）其中R1和R2各自表示苯基，4-甲基苯基或4-甲氧基苯基和0.1至100重量份溶解络合物的有机溶剂，然后在分解温度下加热涂布膜复合，然后焙烧膜，400〜900℃

2. 发明授权

US5508403A Phosphorus pyridine compound 失效
标题翻译：磷吡啶化合物
公开(公告)号：US5508403A
公开(公告)日：1996-04-16
申请号：US463511
申请日：1995-06-05
申请人： Shin-ichi Akiyama , Ryozo Sakoda , Kiyotomo Seto , Norimasa Shudo
发明人： Shin-ichi Akiyama , Ryozo Sakoda , Kiyotomo Seto , Norimasa Shudo
IPC分类号： A61K31/675 , A61K31/44 , A61K31/445 , A61K31/495 , A61K31/535 , A61K31/66 , A61K31/665 , A61P35/00 , A61P43/00 , C07D213/80 , C07F9/58 , C07F9/59 , C07F9/6558 , C07F9/6571 , C07F9/6574
CPC分类号： A61K31/44 , A61K31/445 , A61K31/495 , A61K31/535 , A61K31/66 , A61K31/665 , A61K31/675 , C07F9/587 , C07F9/597 , C07F9/657181
摘要： An agent for enhancing the drug effects of an antitumor drug, which comprises a compound of the formula I: ##STR1## or a pharmaceutically acceptable salt of the compound.
摘要翻译：一种用于增强抗肿瘤药物的药物作用的药剂，其包含式I化合物或其药学上可接受的盐。

3. 发明授权

US5319089A Process for the optical resolution of pyranobenzoxadiazole compounds 失效
标题翻译：吡喃并苯并恶二唑化合物的光学拆分方法
公开(公告)号：US5319089A
公开(公告)日：1994-06-07
申请号：US780357
申请日：1991-10-22
申请人： Hiroo Matsumoto , Kiyotomo Seto , Ryozo Sakoda
发明人： Hiroo Matsumoto , Kiyotomo Seto , Ryozo Sakoda
IPC分类号： C07D498/04
CPC分类号： C07D498/04
摘要： A process for the optical resolution of a pyranobenzoxadiazole compound represented by the formula [(.+-.)I]: ##STR1## which comprises reacting the compound [(.+-.)I] with an optically active carboxylic acid represented by the formula [II]: ##STR2## and separating the diastereomeric salt thus formed is disclosed.
摘要翻译：用于光学拆分由式[（+/-）I]表示的吡喃并苯并恶二唑化合物的方法：包括使化合物[（+/-）I]与光学公开了由式[II]表示的活性羧酸：＆lt; IMAGE＆gt;并分离如此形成的非对映体盐。

4. 发明授权

US5314883A 5-heteroarylamino-6-oxy-substituted 3(2H)-pyridazinones 失效
标题翻译： 5-杂芳基氨基-6-氧基取代的3（2H） - 哒嗪酮
公开(公告)号：US5314883A
公开(公告)日：1994-05-24
申请号：US994404
申请日：1992-12-21
申请人： Keizo Tanikawa , Akira Saito , Takashi Matsumoto , Ryozo Sakoda , Nobutomo Tsuruzoe , Ken-ichi Shikada
发明人： Keizo Tanikawa , Akira Saito , Takashi Matsumoto , Ryozo Sakoda , Nobutomo Tsuruzoe , Ken-ichi Shikada
IPC分类号： A61K31/50 , A61K31/501 , A61P7/02 , C07D237/22 , C07D401/12 , C07D401/14 , C07D403/12 , C07D405/12 , C07D409/12 , C07D409/14 , C07D413/12 , C07D413/14 , C07D417/12
CPC分类号： C07D401/12 , C07D237/22 , C07D405/12
摘要： A compound of the formula: ##STR1## or its pharmaceutically acceptable salt and pharmaceutical compositions containing these compounds as effective ingredients. These compounds have strong antithrombotic activity, cardiotonic activity, vasodilator activity and anti-SRS-A activity, and are useful as prophylactic or therapeutic agents for various thrombotic afflictions, congestive heart failure, hypertension, asthma, immediate-type allergy diseases and the like.
摘要翻译：下式的化合物：其含有这些化合物作为有效成分的药学上可接受的盐和药物组合物。这些化合物具有强的抗血栓活性，强心剂活性，血管扩张剂活性和抗SRS-A活性，可用作各种血栓形成疾病，充血性心力衰竭，高血压，哮喘，立即型过敏性疾病等的预防或治疗剂。

5. 发明授权

US4843076A Dihydropyridine-5-phosphonic acid cyclic ester 失效
标题翻译：二氢吡啶-5-膦酸环酯
公开(公告)号：US4843076A
公开(公告)日：1989-06-27
申请号：US77220
申请日：1987-07-24
申请人： Kiyotomo Seto , Ryozo Sakoda , Hiroo Matsumoto , Yoshimasa Kamikawaji , Sakuya Tanaka
发明人： Kiyotomo Seto , Ryozo Sakoda , Hiroo Matsumoto , Yoshimasa Kamikawaji , Sakuya Tanaka
IPC分类号： C07F9/38 , A61K31/675 , A61P9/08 , C07F9/40 , C07F9/6571 , C07F9/6574
CPC分类号： C07F9/657181
摘要： An optical isomer of a compound having the formula: ##STR1## wherein the two methyl groups at 4- and 6-positions of the dioxaphosphorinane ring assume trans configurations to each other, which has a levo-rotatory angle of optical rotation attributable to the asymmetric carbon atom at 4-position of the dihydropyridine ring, and a pharmaceutically acceptable salt thereof.
摘要翻译：具有下式的化合物的光学异构体：其中二氧杂磷杂环戊烷环的4位和6位上的两个甲基呈现相互构型，其具有归因于旋光的左旋旋角到二氢吡啶环的4-位的不对称碳原子及其药学上可接受的盐。

6. 发明授权

US4839361A Dihydropyridine-5-phosphonic acid cyclic propylene ester 失效
标题翻译：二氢吡啶-5-膦酸环丙烯酯
公开(公告)号：US4839361A
公开(公告)日：1989-06-13
申请号：US792981
申请日：1985-10-30
申请人： Kiyotomo Seto , Sakuya Tanaka , Ryozo Sakoda
发明人： Kiyotomo Seto , Sakuya Tanaka , Ryozo Sakoda
IPC分类号： C07D211/90 , C07F9/59 , C07F9/6571 , C07F9/6574
CPC分类号： C07D211/90 , C07F9/59 , C07F9/597 , C07F9/657181 , C07F9/65742
摘要： A compound of the formula: ##STR1## wherein X is hydrogen or fluorine and n is 2 or 3; or its pharmaceutically acceptable salt.

7. 发明授权

US4188343A Process for preparing anthranylaldehyde derivatives 失效
标题翻译：制备茴香醛衍生物的方法
公开(公告)号：US4188343A
公开(公告)日：1980-02-12
申请号：US973599
申请日：1978-12-27
申请人： Ryozo Sakoda , Isao Hashiba , Kazuo Nagano
发明人： Ryozo Sakoda , Isao Hashiba , Kazuo Nagano
IPC分类号： C07D233/02 , C07D263/04 , C07C91/28
CPC分类号： C07D263/04 , C07D233/02
摘要： Improved process for preparing anthranylaldehyde derivatives of formula: ##STR1## (Z.sup.1 and Z.sup.2 each represents hydrogen atom, a halogen atom, methyl group or trifluoromethyl group.) is provided.The process comprises steps of (1) protecting aldehyde group of a o-halogenobenzaldehyde with a specific alkylamine derivative, then (2) reacting the thus protected compound with a corresponding aniline derivative, and finally, (3) treating the thus obtained product with an acid.The anthranylaldehyde derivatives, i.a. N-(2,6-dichlorophenyl)anthranylaldehyde is useful as an intermediate for preparation of the corresponding anilinophenylacetic acids which are anti-inflammatory and analgesic agents.
摘要翻译：提供了制备下式的下列化合物的蒽衍生物的改进方法：（Z1和Z2各自表示氢原子，卤素原子，甲基或三氟甲基）。该方法包括以下步骤：（1）用特定的烷基胺衍生物保护邻 - 卤代苯甲醛的醛基，然后（2）使所保护的化合物与相应的苯胺衍生物反应，最后，（3）用如下得到的产物酸。苯甲醛衍生物，例如 N-（2,6-二氯苯基）苯甲醛可用作制备相应的抗炎和止痛剂的苯胺基苯基乙酸的中间体。

8. 发明授权

US5304550A Drug effect-enhancing agent for antitumor drug 失效
标题翻译：用于抗肿瘤药物的药物作用增强剂
公开(公告)号：US5304550A
公开(公告)日：1994-04-19
申请号：US57902
申请日：1993-05-07
申请人： Shin-ichi Akiyama , Ryozo Sakoda , Kiyotomo Seto , Norimasa Shudo
发明人： Shin-ichi Akiyama , Ryozo Sakoda , Kiyotomo Seto , Norimasa Shudo
IPC分类号： A61K31/44 , A61K31/445 , A61K31/495 , A61K31/535 , A61K31/66 , A61K31/665 , A61K31/675 , C07F9/58 , C07F9/59 , C07F9/6571 , A61K31/55
CPC分类号： A61K31/44 , A61K31/445 , A61K31/495 , A61K31/535 , A61K31/66 , A61K31/665 , A61K31/675 , C07F9/587 , C07F9/597 , C07F9/657181
摘要： Compounds of the formula (I): ##STR1## in which the nitrogen-containing hetero ring portion is 1,4-dihydropyridine ring or a pyridine ring, R.sup.1 is only present when the nitrogen-containing hetero ring is a 1,4-dihydropyridine ring, and Z is a group of the formula (II): ##STR2## in which R.sup.4 and R.sup.5 may be the same or different and together may form one divalent group, are effective agents for enhancing the antitumor effect of antitumor drugs.
摘要翻译：其中含氮杂环部分为1,4-二氢吡啶环或吡啶环的式（I）化合物：其中R 1仅在含氮杂环为1时存在，并且Z是式（II）的基团：其中R 4和R 5可以相同或不同并且可以一起形成一个二价基团的式（II）的基团是用于增强抗肿瘤效果的有效药剂的抗肿瘤药物。

9. 发明授权

US5130303A Drug effect-enhancing agent for antitumor drug 失效
标题翻译：用于抗肿瘤药物的药物效应增强剂
公开(公告)号：US5130303A
公开(公告)日：1992-07-14
申请号：US729904
申请日：1991-07-15
申请人： Shin-ichi Akiyama , Ryozo Sakoda , Kiyotomo Seto , Norimasa Shudo
发明人： Shin-ichi Akiyama , Ryozo Sakoda , Kiyotomo Seto , Norimasa Shudo
IPC分类号： A61K31/44 , A61K31/445 , A61K31/495 , A61K31/535 , A61K31/66 , A61K31/665 , A61K31/675 , C07F9/58 , C07F9/59
CPC分类号： A61K31/44 , A61K31/445 , A61K31/495 , A61K31/535 , A61K31/66 , A61K31/665 , A61K31/675 , C07F9/587 , C07F9/597
摘要： Compounds of the formula (I): ##STR1## in which the nitrogen-containing hetero ring portion is a 1,4-dihydropyridine ring or a pyridine ring, R.sup.1 is only present when the nitrogen-containing hetero ring is a 1,4-dihydropyridine ring, and Z is either a CO.sub.2 R.sup.8 group or a group of the formula (II): ##STR2## in which R.sup.4 and R.sup.5 may be the same or different and together may form one divalent group, are effective agents for enhancing the antitumor effect or antitumor drugs.

10. 发明授权

US5098900A 3(2H)pyridazinone, process for its preparation and anti-allergic agent containing it 失效
标题翻译： 3（2H）吡咯烷酮，其制备方法和含有其的抗过敏剂
公开(公告)号：US5098900A
公开(公告)日：1992-03-24
申请号：US180599
申请日：1988-04-11
申请人： Motoo Mutsukado , Keizo Tanikawa , Ken-ichi Shikada , Ryozo Sakoda
发明人： Motoo Mutsukado , Keizo Tanikawa , Ken-ichi Shikada , Ryozo Sakoda
IPC分类号： A61K31/50 , A61K31/535 , A61P11/00 , A61P11/08 , A61P27/16 , A61P37/08 , C07D237/00 , C07D237/14 , C07D237/22 , C07D317/00 , C07D405/12
CPC分类号： C07D405/12 , C07D237/22 , Y10S514/826
摘要： A 3(2H)pyridazinone of the formula: ##STR1## wherein R.sub.1 is C.sub.2 -C.sub.5 alkyl; R.sub.2 is hydrogen, C.sub.1 -C.sub.3 alkyl, chlorine or bromine; R.sub.3 is hydrogen or C.sub.1 -C.sub.4 alkyl; and each of Y.sub.1, Y.sub.2 and Y.sub.3 which may be the same or different, is hydrogen, C.sub.1 -C.sub.8 alkyl, C.sub.2 -C.sub.8 alkenyl, halogen, --(CH.sub.2).sub.l A [wherein A is substituted amino of the formula --N(R.sub.4) (R.sub.5) (wherein each of R.sub.4 and R.sub.5 which may be the same or different, is C.sub.1 -C.sub.4 alkyl, or R.sub.4 and R.sub.5 together form C.sub.4 -C.sub.6 alkylene), morpholino, 4-R.sub.6 -piperazin-1-yl (wherein R.sub.6 is C.sub.1 -C.sub.3 alkyl) or --OR.sub.7 (wherein R.sub.7 is hydrogen or C.sub.1 -C.sub.3 alkyl), and l is an integer of 0 to 3], --OR.sub.8 [wherein R.sub.8 is hydrogen, C.sub.1 -C.sub.8 alkyl, C.sub.3 -C.sub.5 alkenyl, benzyl or --(CH.sub.2).sub.q --R.sub.9 [wherein R.sub.9 is CO.sub.2 R.sub.3 (wherein R.sub.3 is as defined above), --CONHR.sub.3 (wherein R.sub.3 is as defined above) or --CH.sub.2 OR.sub.7 (wherein R.sub.7 is as defined above), and q is an integer of 1 to 5]], --CO.sub.2 R.sub.3 (wherein R.sub.3 is as defined above), --CON(R.sub.10) (R.sub.11) [wherein each of R.sub.10 and R.sub.11 which may be the same or different, is hydrogen, C.sub.1 -C.sub.4 alkyl or C.sub.3 -C.sub.5 alkenyl, or R.sub.10 and R.sub.11 together form C.sub.4 -C.sub.6 alkylene, --(CH.sub.2).sub.2 O(CH.sub.2).sub.2 -- or --(CH.sub.2).sub.2 N(R.sub.6)(CH.sub.2).sub.2 -- (wherein R.sub.6 is as defined above)], --CONH(CH.sub.2).sub.m A (wherein A is as defined above, and m is an integer of 2 to 4), --CH.dbd.CHCOR.sub.12 (wherein R.sub.12 is hydroxy, C.sub.1 -C.sub.4 alkoxy or --N(R.sub.13) (CH.sub.2).sub.n CO.sub.2 R.sub.3 (wherein R.sub.13 is hydrogen, C.sub.1 -C.sub.6 alkyl or cycloalkyl, R.sub.3 is as defined above, and n is an integer of 1 to 4)), --SR.sub.14 (wherein R.sub.14 is C.sub.1 -C.sub.4 alkyl), --CN or ##STR2## wherein R.sub.3 is as defined above), or two of Y.sub.1, Y.sub.2 and Y.sub.3 together form ##STR3## (wherein p is an integer of 1 or 2), and a pharmaceutically acceptable salt thereof.
摘要翻译：具有下式的3（2H）哒嗪酮：其中R 1是C 2 -C 5烷基; R2是氢，C1-C3烷基，氯或溴; R3是氢或C1-C4烷基; 并且可以相同或不同的Y 1，Y 2和Y 3各自为氢，C 1 -C 8烷基，C 2 -C 8烯基，卤素， - （CH 2）l A [其中A为式-N（R 4）（R 5）（其中可以相同或不同的R 4和R 5各自为C 1 -C 4烷基，或R 4和R 5一起形成C 4 -C 6亚烷基），吗啉代，4-R 6 - 哌嗪-1-基（其中R 6 是C 1 -C 3烷基）或-OR 7（其中R 7是氢或C 1 -C 3烷基），l是0-3的整数]，-OR 8 [其中R8是氢，C1-C8烷基，C3-C5链烯基，苄基或 - （CH 2）q -R 9 [其中R 9是CO 2 R 3（其中R 3如上定义），-CONHR 3（其中R 3如上定义）或-CH 2 OR 7（其中R 7如上所定义），q是整数 1〜5]]，-CO 2 R 3（其中R 3如上定义），-CON（R 10）（R 11）[其中R 10和R 11可以相同或不同，为氢，C 1 -C 4烷基或C 3 （CH 2）2 O（CH 2）2 - 或 - （CH 2）2 N（R 6）（CH 2）2 - （其中R 6如上所定义）]， - （C 1 -C 6）烷基，或者R 10和R 11一起形成C 1 -C 6亚烷基， CONH（CH2）mA（其中在A中如上所定义，m为2〜4的整数），-CH = CHCOR 12（其中，R 12为羟基，C 1〜C 4烷氧基或-N（R 13）（CH 2）n CO 2 R 3（式中，R 13为氢， C6烷基或环烷基，R3如上所定义，n是1至4的整数）），-SR 14（其中R 14是C 1 -C 4烷基），-CN或其中R 3如上定义），或 Y1，Y2和Y3中的两个一起形成（其中p为1或2的整数）及其药学上可接受的盐。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式